Thomas E. Boyd

3.8k citations

56 papers · 2.4k indexed · 1 hit paper · h-index 22

Impact in

Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Genetics 39
- Chronic Lymphocytic Leukemia Research 34
Pathology and Forensic Medicine 22
- Lymphoma Diagnosis and Treatment 22

Co-authors: Nathan Fowler (19 shared papers)Jeff P. Sharman (22 shared papers)Richard R. Furman (15 shared papers)Kathryn S. Kolibaba (7 shared papers)Ranjana H. Advani (6 shared papers)Sonali M. Smith (5 shared papers)Ahmed Hamdy (4 shared papers)Barbara Grant (3 shared papers)
Journals: Blood (23 papers)Journal of Clinical Oncology (15 papers)Investigational New Drugs (2 papers)Leukemia Research (2 papers)The Oncologist (2 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Thomas E. Boyd

55 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies 2012 · 848 citations

Peers

Countries citing papers authored by Thomas E. Boyd

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Boyd more than expected).

Fields of papers citing papers by Thomas E. Boyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Boyd. The network helps show where Thomas E. Boyd may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas E. Boyd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas E. Boyd Line = papers co-authored together Thomas E. Boyd links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Journal of Clinical Oncology ·Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Sara Rodríguez, Betty Chang, Juthamas Sukbuntherng, Raquel Izumi, Ahmed Hamdy, Eric Hedrick, Nathan Fowler Hit paper breakdown →	2012	848
2	Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Journal of Clinical Oncology ·Susan O’Brien, Joseph O. Moore, Thomas E. Boyd, Loree Larratt, Aleksander B. Skotnicki, Benjamín Koziner, Asher Chanan‐Khan, John F. Seymour, R. Gregory Bociek, Steve Pavletic, R. Kanti	2007	217
3	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer European Urology ·Heather H. Cheng, Colin C. Pritchard, Thomas E. Boyd, Peter S. Nelson, Bruce Montgomery	2015	188
4	5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Journal of Clinical Oncology ·Susan O’Brien, Joseph O. Moore, Thomas E. Boyd, Loree Larratt, Aleksander B. Skotnicki, Benjamín Koziner, Asher Chanan‐Khan, John F. Seymour, John G. Gribben, Loretta M. Itri, R. Kanti	2009	125
5	Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma Blood ·Nicholas Di Bella, Raymond Taetle, Kathryn S. Kolibaba, Thomas E. Boyd, Robert N. Raju, David Barrera, Ernest W. Cochran, Philip Y. Dien, Roger M. Lyons, Peter J. Schlegel, Svetislava J. Vukelja, Julie Boston, Kristi A. Boehm, Yunfei Wang, Lina Asmar	2009	63
6	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) Blood ·Peter Hillmen, Tadeusz Robak, Ann Janssens, K. Govindbabu, Sebastian Grosicki, Jiřı́ Mayer, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Thomas E. Boyd, Marco Montillo, Astrid McKeown, Jodi Carey, Ira Gupta, Chai‐Ni Chang, Steen Lisby, Fritz Offner	2013	58
7	Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy Cancer Immunology Immunotherapy ·David A. Smith, Paul Conkling, Donald Richards, John Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice Bexon	2014	58
8	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma Investigational New Drugs ·Tycel Phillips, Paul M. Barr, Steven I. Park, Kathryn S. Kolibaba, Paolo F. Caimi, Saurabh Chhabra, Edwin Kingsley, Thomas E. Boyd, Robert Chen, Anne-Sophie Carret, Elaina M. Gartner, Hong Li, Cindy Chen Yu, David C. Smith	2018	57
9	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer Investigational New Drugs ·Giorgio V. Scagliotti, Jin Hyoung Kang, David C. Smith, Richard K. Rosenberg, Keunchil Park, Sang-We Kim, Wu‐Chou Su, Thomas E. Boyd, Donald Richards, Silvia Novello, Scott M. Hynes, Scott P. Myrand, Ji Lin, Emily Nash Smyth, Sameera R. Wijayawardana, Aimee Bence Lin, Mary Pinder-Schenck	2016	55
10	A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma Cancer ·Sumanta K. Pal, Andres Forero‐Torres, John A. Thompson, John C. Morris, Saurabh Chhabra, Christopher Hoimes, Nicholas J. Vogelzang, Thomas E. Boyd, Paulo Gustavo Bergerot, Jacob J. Adashek, Hong Li, Xuesong Yu, Elaina M. Gartner, Anne‐Sophie Carret, David C. Smith	2019	54
11	Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases The Oncologist ·Costantine Albany, Lawrence H. Einhorn, Lawrence Garbo, Thomas E. Boyd, Neil C. Josephson, Darren R. Feldman	2017	40
12	The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma Blood ·Nathan Fowler, Ranjana H. Advani, Jeff P. Sharman, Sonali M. Smith, Jesse McGreivy, Lori Kunkel, Vina Troung, Cathy Zhou, Thomas E. Boyd	2012	38
13	The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study Blood ·Nathan Fowler, Jeff Porte Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Joseph J. Buggy, David Loury, Ahmed Hamdy, Ranjana H. Advani	2010	36
14	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia The Oncologist ·Christopher R. Cogle, Bart L. Scott, Thomas E. Boyd, Guillermo Garcia‐Manero	2015	31
15	Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. Journal of Clinical Oncology ·Jacqueline C. Barrientos, Richard R. Furman, John P. Leonard, Ian W. Flinn, Kanti Roop, Sven de Vos, Marshall T. Schreeder, Nina D. Wagner‐Johnston, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Leanne Holes, David M. Johnson, Daniel Li, Roger Dansey, Thomas M. Jahn, Steven Coutré	2013	31
16	Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood ·R. Kanti, Joseph O. Moore, Thomas E. Boyd, Loree Larratt, A. Golenkov, Benjamín Koziner, Asher Chanan‐Khan, R. Gregory Bociek, Loretta M. Itri	2004	30
17	Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study Blood ·Steven Coutré, John P. Leonard, Richard R. Furman, Jacqueline C. Barrientos, Sven de Vos, Ian W. Flinn, Marshall T. Schreeder, Nina D. Wagner‐Johnston, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Leanne Holes, Brian J. Lannutti, Dave M. Johnson, Langdon L. Miller, Thomas M. Jahn	2012	30
18	A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood ·Jeff P. Sharman, Sven de Vos, John P. Leonard, Richard R. Furman, Steven Coutré, Ian W. Flinn, Marshall T. Schreeder, Jacqueline C. Barrientos, Nina D. Wagner‐Johnston, Thomas E. Boyd, Nathan Fowler, Leanne Holes, Brian J. Lannutti, David M. Johnson, Thomas M. Jahn, Langdon L. Miller	2011	28
19	Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies The Journal of Clinical Pharmacology ·Eric Laille, Michael R. Savona, Bart L. Scott, Thomas E. Boyd, Qian Dong, Barry Skikne	2013	26
20	A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma British Journal of Haematology ·Lihua E. Budde, Michelle M. Zhang, Andrei R. Shustov, John M. Pagel, Ted Gooley, George R. Oliveira, Tara L. Chen, Nancy Knudsen, Jennifer E. Roden, Britt Kammerer, Shani L. Frayo, Thomas A. Warr, Thomas E. Boyd, Oliver W. Press, Ajay K. Gopal	2013	26

About Thomas E. Boyd

Thomas E. Boyd is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Pulmonary and Respiratory Medicine, having authored 56 papers that have together received 2.4k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (22 papers), Immunodeficiency and Autoimmune Disorders (10 papers), Chronic Myeloid Leukemia Treatments (9 papers), Lung Cancer Treatments and Mutations (8 papers), Acute Myeloid Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (7 papers) and Viral-associated cancers and disorders (4 papers). The work is most often cited by research in Genetics (1.4k citations), Pathology and Forensic Medicine (1.2k citations), Hematology (495 citations), Oncology (727 citations) and Immunology (555 citations). Thomas E. Boyd has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Nathan Fowler, Jeff P. Sharman, Richard R. Furman, Kathryn S. Kolibaba, Ranjana H. Advani, Sonali M. Smith, Ahmed Hamdy, Barbara Grant, Joseph J. Buggy and Eric Hedrick. Their work appears in journals such as Blood, Journal of Clinical Oncology, Investigational New Drugs, Leukemia Research and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact